Subscribe
africa-studio-shutterstock-com-5
Africa Studio / Shutterstock.com
9 June 2016Americas

Judge overturns $200m award in Gilead v Merck

A US court has overturned an earlier ruling in which Merck was awarded $200 million in damages for patent infringement after finding that the pharmaceutical company had engaged in misconduct.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
US Supreme Court refuses to hear appeal against ‘unclean hands’ decision
10 January 2019   The US Supreme Court has refused to hear an appeal against a ruling that American pharmaceutical firm Merck & Co cannot collect $200 million in damages due to its misconduct during a trial.
Americas
Federal Circuit affirms Merck ‘unclean hands’ verdict
26 April 2018   The US Court of Appeals for the Federal Circuit has affirmed a finding that pharmaceutical company Merck had engaged in misconduct and was not allowed to bring an action against Gilead.
Americas
Merck to pay Gilead $14m in attorneys’ fees
20 July 2017   A California district court has awarded Gilead Sciences $13.8 million in attorneys’ fees in a patent dispute against Merck & Co, Merck Sharp & Dohme and Isis Pharmaceuticals.


Editor's picks

AstraZeneca unit faces class-action suit over alleged Soliris monopoly
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

Editor's picks

Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025
Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025
Americas
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025
Americas
‘Lift as you climb’: Abbott, BMS, Hitachi, LEGO Group counsels explore ‘empowerment’
6 March 2025
Careers
Jones Day adds experienced patent litigators from Weil
4 March 2025

More on this story

Americas
US Supreme Court refuses to hear appeal against ‘unclean hands’ decision
10 January 2019   The US Supreme Court has refused to hear an appeal against a ruling that American pharmaceutical firm Merck & Co cannot collect $200 million in damages due to its misconduct during a trial.
Americas
Federal Circuit affirms Merck ‘unclean hands’ verdict
26 April 2018   The US Court of Appeals for the Federal Circuit has affirmed a finding that pharmaceutical company Merck had engaged in misconduct and was not allowed to bring an action against Gilead.
Americas
Merck to pay Gilead $14m in attorneys’ fees
20 July 2017   A California district court has awarded Gilead Sciences $13.8 million in attorneys’ fees in a patent dispute against Merck & Co, Merck Sharp & Dohme and Isis Pharmaceuticals.

More on this story

Americas
US Supreme Court refuses to hear appeal against ‘unclean hands’ decision
10 January 2019   The US Supreme Court has refused to hear an appeal against a ruling that American pharmaceutical firm Merck & Co cannot collect $200 million in damages due to its misconduct during a trial.
Americas
Federal Circuit affirms Merck ‘unclean hands’ verdict
26 April 2018   The US Court of Appeals for the Federal Circuit has affirmed a finding that pharmaceutical company Merck had engaged in misconduct and was not allowed to bring an action against Gilead.
Americas
Merck to pay Gilead $14m in attorneys’ fees
20 July 2017   A California district court has awarded Gilead Sciences $13.8 million in attorneys’ fees in a patent dispute against Merck & Co, Merck Sharp & Dohme and Isis Pharmaceuticals.

More features

Fenwick establishes new Boston office with trio of IP partners from Cooley
How pharma should prep for the six-bill avalanche from Congress
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
USPTO speeds up patent issuance amid widespread agency changes
Lathrop GPM adds portfolio management specialist
Fed Circ decides fate of Orange Book patent covering blockbuster J&J schizophrenia drug
Failure to make findings of fact adds twist to battle over Eliquis in Ireland
Novo Nordisk, Bayer, GSK among giants accused in drug delivery suits